Hematopoietic Stem Cell Transplantation (HSCT) is the only potentially curative treatment option for the hematologic complications that occur in patients with Fanconi anemia (FA). In this study, we present a retrospective multicenter analysis from the Eastern Mediterranean Blood and Marrow Transplantation Group (EMBMT) of matched related donor HSCT for FA in adolescents and adults transplanted between 1988 and 2015. Forty-five patients received HSCT with a median age at transplant of 18 years, the interquartile range (IQR) (15–23.5); 25 (55.6%) patients were females and 20 (44.4%) were males. Conditioning regimen was fludarabine-based in 29 (64.4%) patients, irradiation-based in five (11.1%) patients, and the remaining patients received other combinations. Indication for HSCT was bone marrow failure in 39 (86.7%) and myelodysplastic syndrome in six (13.3%) patients. Stem cell source was bone marrow in 22 (48.9%), peripheral blood in 20 (44.4%), umbilical cord blood in one (2.2%), and combination of bone marrow and cord blood in two (4.4%) patients. Twenty-seven (60%) patients engrafted and five (11.1%) had primary engraftment failure. The median time to neutrophil engraftment was 14 days (range 10–21 days); median time for platelet engraftment was 17 days (10–33 days). The probability of developing grade II–IV acute GVHD for all patients was 7.0% and chronic GVHD 36.6%. No new malignancies were reported. The OS probability was 53.6% (95% CI, 38.3–68.9%) with a median follow-up of 13 months (95% CI, 1–240). Our HLA-matched related HSCT results in AYA patients with FA compare favorably with other reported international registry data.
Subscribe to Journal
Get full journal access for 1 year
only $41.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Fanconi G. Familial constitutional panmyelocytopathy, Fanconi’s anemia (F.A.). I. Clinical aspects. Semin Hematol. 1967;4:233–40.
Alter BP. Fanconi’s anemia and malignancies. Am J Hematol. 1996;53:99–110. e-pub ahead of print 1996/10/01; 10.1002/(SICI)1096-8652(199610)53:2<99::AID-AJH7>3.0.CO;2-Z
Alter BP. The bone marrow failure syndromes. In: Nathan DG, Oski FA, editors. Hematology of infancy and childhood. Philadelphia, PA: Saunders; 2003. p. 237.
Butturini A, Gale RP, Verlander PC, Adler-Brecher B, Gillio AP, Auerbach AD. Hematologic abnormalities in Fanconi anemia: an International Fanconi Anemia Registry Study. Blood. 1994;84:1650–5. e-pub ahead of print 1994/09/01
Kutler DI, Singh B, Satagopan J, Batish SD, Berwick M, Giampietro PF, et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood. 2003;101:1249–56. https://doi.org/10.1182/blood-2002-07-2170. e-pub ahead of print 2002/10/24
Rosenberg PS, Greene MH, Alter BP. Cancer incidence in persons with Fanconi anemia. Blood. 2003;101:822–6. https://doi.org/10.1182/blood-2002-05-1498. e-pub ahead of print 2002/10/24
Socie G, Devergie A, Girinski T, Piel G, Ribaud P, Esperou H, et al. Transplantation for Fanconi’s anaemia: long-term follow-up of fifty patients transplanted from a sibling donor after low-dose cyclophosphamide and thoraco-abdominal irradiation for conditioning. Br J Haematol. 1998;103:249–55. e-pub ahead of print 1998/10/29
MacMillan ML, Davies SM, Orchard PJ, Ramsay NK, Wagner JE. Haemopoietic cell transplantation in children with juvenile myelomonocytic leukaemia. Br J Haematol. 1998;103:552–8. e-pub ahead of print 1998/11/25
Berger R, Bernheim A, Gluckman E, Gisselbrecht C. In vitro effect of cyclophosphamide metabolites on chromosomes of Fanconi anaemia patients. Br J Haematol. 1980;45:565–8. e-pub ahead of print 1980/08/01
Gluckman E, Devergie A, Dutreix J. Radiosensitivity in Fanconi anaemia: application to the conditioning regimen for bone marrow transplantation. Br J Haematol. 1983;54:431–40. e-pub ahead of print 1983/07/01
Deeg HJ, Socie G, Schoch G, Henry-Amar M, Witherspoon RP, Devergie A, et al. Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood. 1996;87:386–92. e-pub ahead of print 1996/01/01
Kapelushnik J, Or R, Slavin S, Nagler A. A fludarabine-based protocol for bone marrow transplantation in Fanconi’s anemia. Bone Marrow Transpl. 1997;20:1109–10. https://doi.org/10.1038/sj.bmt.1701016. e-pub ahead of print 1998/02/18
Aker M, Varadi G, Slavin S, Nagler A. Fludarabine-based protocol for human umbilical cord blood transplantation in children with Fanconi anemia. J Pediatr Hematol Oncol. 1999;21:237–9. e-pub ahead of print 1999/06/11
Bitan M, Or R, Shapira MY, Aker M, Resnick IB, Ackerstein A, et al. Fludarabine-based reduced intensity conditioning for stem cell transplantation of Fanconi anemia patients from fully matched related and unrelated donors. Biol Blood Marrow Transpl. 2006;12:712–8. https://doi.org/10.1016/j.bbmt.2006.03.002. e-pub ahead of print 2006/06/21
Maschan AA, Trakhtman PE, Balashov DN, Shipicina IP, Skorobogatova EV, Skvortsova YV, et al. Fludarabine, low-dose busulfan and antithymocyte globulin as conditioning for Fanconi anemia patients receiving bone marrow transplantation from HLA-compatible related donors. Bone Marrow Transpl. 2004;34:305–7. https://doi.org/10.1038/sj.bmt.1704580. e-pub ahead of print 2004/06/15
Tan PL, Wagner JE, Auerbach AD, Defor TE, Slungaard A, Macmillan ML. Successful engraftment without radiation after fludarabine-based regimen in Fanconi anemia patients undergoing genotypically identical donor hematopoietic cell transplantation. Pediatr Blood Cancer. 2006;46:630–6. https://doi.org/10.1002/pbc.20538. e-pub ahead of print 2005/08/04
Ben Halim N, Hsouna S, Lasram K, Rejeb I, Walha A, Talmoudi F, et al. Differential impact of consanguineous marriages on autosomal recessive diseases in Tunisia. Am J Hum Biol. 2016;28:171–80. https://doi.org/10.1002/ajhb.22764. e-pub ahead of print 2015/07/17
Aljurf M, Nassar A, Hamidieh AA, Elhaddad A, Hamladji RM, Bazarbachi A, et al. Hematopoietic stem cell transplantation in the Eastern Mediterranean Region (EMRO) 2011–2012: a comprehensive report on behalf of the Eastern Mediterranean Blood and Marrow Transplantation Group (EMBMT). Hematol Oncol Stem Cell Ther. 2015;8:167–75. https://doi.org/10.1016/j.hemonc.2015.09.002. e-pub ahead of print 2015/10/11
Bierings M, Bonfim C, Peffault De Latour R, Aljurf M, Mehta PA, Knol C, et al. Transplant results in adults with Fanconi anaemia. Br J Haematol. 2018;180:100–9. https://doi.org/10.1111/bjh.15006. e-pub ahead of print 2017/11/03
Peffault de Latour R, Porcher R, Dalle JH, Aljurf M, Korthof ET, Svahn J, et al. Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience. Blood. 2013;122:4279–86. https://doi.org/10.1182/blood-2013-01-479733. e-pub ahead of print 2013/10/23
Gluckman E, Auerbach AD, Horowitz MM, Sobocinski KA, Ash RC, Bortin MM, et al. Bone marrow transplantation for Fanconi anemia. Blood. 1995;86:2856–62. e-pub ahead of print 1995/10/01
Conflict of interest
The authors declare that they have no conflict of interest.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
AlDawsari, G., Elhaddad, A., El Fakih, R. et al. Outcome of hematopoietic stem cell transplantation (HCT) from HLA-matched related donor for Fanconi anemia (FA) in adolescents and adults: a retrospective study by Eastern Mediterranean Blood and Marrow Transplantation Group (EMBMT). Bone Marrow Transplant 55, 1485–1490 (2020). https://doi.org/10.1038/s41409-020-0809-5